Britain and America have hammered out a major bilateral deal that will preserve no levies on UK pharmaceutical products going into the American market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase expenditure on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these crucial exports will remain at nothing for a timeframe of 36 months.
This agreement comes after earlier threats to significantly raise duties on branded drug imports, with potential rates floated reaching double the cost.
"This deal between the Britain reinforces the global environment for new treatments and establishes long-overdue fairness to transatlantic pharmaceutical trade," an announcement said.
Trade Significance
Drugs constitute one of the Britain's most significant exports to the US, which is clearly the primary destination for large British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to the third quarter, the UK shipped medicines totaling over eleven billion pounds to the US. This value made up a significant portion of British export trade in that period.
"This deal secures employment, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments topped twenty percent.
Industry Background
This agreement comes amid a long-running row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were exacerbated by claims that American patients were paying a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while multi-billion-dollar expansions have been pledged toward US facilities.
One official acknowledged that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.
